The Serum Institute of India (SII) is set to begin its phase-2 human clinical trials of the Oxford University-AstraZeneca Covid-19 vaccine candidate, Covishield, on Tuesday. The observer-blind, randomised and controlled study to determine the safety and immunogenicity of ‘Covishield’ on healthy Indian adults will begin at Bharati Vidyapeeth Medical College and Hospital in Pune, sources … Continue reading Phase-2 trial of Oxford Covid-19 vaccine to begin at PGIMER today